<DOC>
	<DOC>NCT01111279</DOC>
	<brief_summary>The purpose of this study is to assess the safety and tolerability of gpASIT+TM administered subcutaneously in absence or in presence of an immunoregulating adjuvant in grass pollen allergic patients.</brief_summary>
	<brief_title>Clinical Safety and Tolerability Study of gpASIT+TM and gpASIT+TM/Immunoregulating Adjuvant to Treat Seasonal Grass Pollen Rhinoconjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<criteria>Subject has given written informed consent Age between 18 and 50 years The subjects are in good physical and mental health according to his/her medical history, vital signs, and clinical status Male or non pregnant, nonlactating female Females unable to bear children must have documentation of such in the CRF (i.e. tubule ligation, hysterectomy, or post menopausal (defined as a minimum of one year since the last menstrual period)) Allergy diagnosis: A history of seasonal allergic rhinoconjunctivitis (SAR) during the grass pollen season during at least during the two previous years A positive skin prick test (wheal diameter ≥ 3 mm) to grasspollen mixture Specific IgE against grass pollen (RAST class 2 or IgE &gt; 0.7 kU/l) Asymptomatic to perennial inhalant allergens even if shown to be hypersensitive in a skin prick test. Subjects with current or past immunotherapy (any time in the past) A history of hypersensitivity to the excipients Subjects requiring control medication against asthma (bronchodilator nebulised drugs or local or systemic corticosteroids) Subjects with documented evidence of acute or significant chronic sinusitis (as determined by investigator) Subjects with a history of hepatic or renal disease Subjects symptomatic to perennial inhalant allergens Subjects with rhinitis medicamentosa, nonspecific rhinitis (to food dye, preservative agent…) Subject with malignant disease, autoimmune disease (and family medical history of autoimmune disease) Any chronic disease, which may impair the subject's ability to participate in the trial (i.e. severe congestive heart failure, active gastric or duodenal ulcer, uncontrolled diabetes mellitus, etc…) Subjects requiring betablockers medication Chronic use of concomitant medications that would affect assessment of the effectiveness of the trial medication (e.g. tricyclic antidepressants) Subject with febrile illness (&gt; 37.5°C, oral) A known positive serology for HIV1/2, HBs antigen or antiHCV antibodies The subject is immunocompromised by medication or illness, has received a vaccine, corticoids or immunosuppressive medications within 1 month before trial entry Receipt of blood or a blood derivative in the past 6 months preceding trial entry Regular consumption of corticoids (oral, topic or nasal) or of antihistaminic drugs within 4 weeks preceding the trial Any consumption of corticoids (oral, topic or nasal) or of antihistaminic drugs within 1 week preceding the trial Use of longacting antihistamines Female subjects who are pregnant, lactating, or of childbearing potential and not protected from pregnancy by a sufficiently reliable method (OCs, IUD) Any condition which could be incompatible with protocol understanding and compliance Subjects who have forfeited their freedom by administrative or legal award or who are under guardianship Unreliable subjects including noncompliant subjects, subjects with known alcoholism or drug abuse or with a history of a serious psychiatric disorder as well as subjects unwilling to give informed consent or to abide by the requirements of the protocol Subjects without means of contacting the investigator rapidly in case of emergency, or not able to be contacted rapidly by the investigator Participation in another clinical trial and/or treatment with an experimental drug within 1 month of trial start Subjects who participated to trial BTTgpASIT003 and were in the treated groups</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>